Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities
Ganina A. Askarov M. Kozina L. Karimova M. Shayakhmetov Y. Mukhamedzhanova P. Brimova A. Berikbol D. Chuvakova E. Zaripova L. Baigenzhin A.
December 2024Multidisciplinary Digital Publishing Institute (MDPI)
Advances in Respiratory Medicine
2024#92Issue 6504 - 525 pp.
Highlights: What are the main findings? The article explores the use of autologous activated lymphocytes with their ability to elicit robust anti-tumor immune responses as a promising complex treatment strategy for lung cancer. The application of various types of T-cell therapy in complex lung cancer treatment in >2000 patients, with a special focus on the autologous activated lymphocytes and infusion protocols, was examined and thoroughly discussed. The article emphasizes the benefits of combining activated lymphocyte therapy with existing treatments like radiation therapy, checkpoint inhibitors, and chemotherapy to improve efficacy and reduce resistance. What are the implications of the main finding? Various cell types like natural killer cells, cytotoxic T lymphocytes, lymphokine-activated killer cells, and tumor-infiltrating lymphocytes contribute to immune responses that assist in eliminating cancer cells. The potential research gaps are identified, and a wider adoption of immune cell therapy as a component of combination strategies for the treatment of lung cancer is proposed. The article highlights ongoing research into the tumor microenvironment and its role in immune evasion, suggesting that targeting these mechanisms could boost treatment success, and discusses the significance of clinical trials in validating the effectiveness of activated lymphocyte therapies and the importance of real-world evidence in guiding clinical practice. This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy like combined immunotherapy and radiation therapy.
activation , immunosuppression , immunotherapy , lung cancer , lymphocytes , tumor
Text of the article Перейти на текст статьи
JSC National Scientific Medical Center, Astana, 010009, Kazakhstan
International Oncological Tomotherapy Center “YMIT”, 010009, Astana, Kazakhstan
JSC National Scientific Medical Center
International Oncological Tomotherapy Center “YMIT”
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026